Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TOCILIZUMAB Cause Complication associated with device? 39 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 39 reports of Complication associated with device have been filed in association with TOCILIZUMAB (Tocilizumab-anoh). This represents 0.0% of all adverse event reports for TOCILIZUMAB.

39
Reports of Complication associated with device with TOCILIZUMAB
0.0%
of all TOCILIZUMAB reports
1
Deaths
21
Hospitalizations

How Dangerous Is Complication associated with device From TOCILIZUMAB?

Of the 39 reports, 1 (2.6%) resulted in death, 21 (53.8%) required hospitalization.

Is Complication associated with device Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TOCILIZUMAB. However, 39 reports have been filed with the FAERS database.

What Other Side Effects Does TOCILIZUMAB Cause?

Drug ineffective (32,342) Rheumatoid arthritis (20,652) Pain (18,384) Off label use (18,256) Arthralgia (15,536) Joint swelling (14,831) Fatigue (13,802) Rash (12,327) Drug intolerance (11,952) Contraindicated product administered (11,547)

What Other Drugs Cause Complication associated with device?

ETONOGESTREL (6,047) COPPER (1,083) BACLOFEN (525) TREPROSTINIL (422) EPOPROSTENOL (399) LEVONORGESTREL (344) ADALIMUMAB (269) CARBIDOPA\LEVODOPA (169) MACITENTAN (169) TEDUGLUTIDE (133)

Which TOCILIZUMAB Alternatives Have Lower Complication associated with device Risk?

TOCILIZUMAB vs TOCILIZUMAB-AAZG TOCILIZUMAB vs TOCOPHEROL TOCILIZUMAB vs TOFACITINIB TOCILIZUMAB vs TOFERSEN TOCILIZUMAB vs TOLNAFTATE

Related Pages

TOCILIZUMAB Full Profile All Complication associated with device Reports All Drugs Causing Complication associated with device TOCILIZUMAB Demographics